Vanguard Intermediate-Term Bond ETF (BIV) Research
This exchange-traded fund aims to mirror the investment outcomes of the Bloomberg U.S. 5–10 Year Government/Credit Float Adjusted Index. This particular benchmark is a market-capitalization-weighted index composed exclusively of investment-grade bonds, which collectively possess a dollar-weighted average maturity between five and ten years. The ETF's portfolio is primarily allocated to U.S. government securities, high-quality corporate debt, and investment-grade international bonds all denominated in U.S. dollars. Its operation is characteristic of passive management, employing an index sampling approach to achieve its objectives.
Market snapshot
- Symbol
- BIV
- Price
- $76.53
- Day change
- +0.29%
- Market cap
- $52.3B
- 52-week range
- 75.63-79.09
- Sector
- Financial Services
- Industry
- Asset Management - Bonds
Peer companies
- Vanguard Short-Term Bond ETF (BSV)
- iShares 20+ Year Treasury Bond ETF (TLT)
- Vanguard Intermediate-Term Bond Index Fund Admiral Shares (VBILX)
- Vanguard Short-Term Bond Index Fund Admiral Shares (VBIRX)
- Vanguard Intermediate-Term Corporate Bond ETF (VCIT)
- Vanguard Short-Term Corporate Bond ETF (VCSH)
- Vanguard Short-Term Corporate Bond Index Fund Admiral Shares (VSCSX)
- Vanguard Tax-Exempt Bond Index Fund Admiral Shares (VTEAX)
Recent insider activity
- PERSEUS SOROS BIOPHARMACEUTICAL FUND LP — C-Conversion (750000 shares) on 2004-12-13
- PERSEUS SOROS BIOPHARMACEUTICAL FUND LP — C-Conversion (1500000 shares) on 2004-12-13
- PERSEUS SOROS BIOPHARMACEUTICAL FUND LP — J-Other (1500000 shares) on 2004-12-13
- Dunker Kristen Marie — trade (55000 shares) on 2006-06-21
- PERSEUS SOROS BIOPHARMACEUTICAL FUND LP — P-Purchase (375044 shares) on 2004-05-13
Open Vanguard Intermediate-Term Bond ETF (BIV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.